GlassScriptPhysician profile
Hyacinth Thomas
NPI 1164402343
$18,906.60
in general payments reported to CMS, 2019-2025
48 companies · $3,277 in 2025
The $3,277 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,011 · 2022: $4,741 · 2023: $2,533 · 2024: $5,344 · 2025: $3,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,613 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,005 · Consulting Fee: $1,152 · Honoraria: $350 · Travel and Lodging: $34.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,613.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,005.02 |
| Consulting Fee | $1,152.00 |
| Honoraria | $350.00 |
| Travel and Lodging | $34.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $4,572.22 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $3,972.75 | 2021-2025 | |
| Novo Nordisk INC | $1,951.36 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $1,178.83 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $729.15 | 2021-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $679.05 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Medtronic, INC. | $611.55 | 2021-2025 | Minimed 780g |
| Insulet Corporation | $574.20 | 2021-2025 | Omnipod |
| Vertex Pharmaceuticals Incorporated | $480.00 | 2021 | |
| Becton, Dickinson and Company | $368.81 | 2022-2023 | |
| Mannkind Corporation | $304.50 | 2021-2025 | Afrezza |
| Dexcom, INC. | $292.39 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Beta Bionics, INC. | $289.80 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $281.40 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $228.13 | 2021-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyacinth Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.